PRS-060: First-in-Class Inhaled IL4Ra Antagonist for Asthma

Candidate Targets Indication Partner Our Commercial
Rights
Discovery Preclinical IND-
enabling
Phase I Phase Ib/IIa
PRS-060 IL4Ra Asthma U.S. Co-commercialization
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase in progress
Phase 1 not started
Phase 2 not started

PRS-060 serves to treat moderate to severe asthma through direct delivery of a potent IL4Ra-targeting Anticalin protein to the lungs. A large proportion of asthma patients suffer from a disorder in the Th2 pathway, where the cytokines IL-4 and IL-13 play an important role. Both cytokines signal via IL4Ra, making IL4Ra a cornerstone intervention point. PRS-060 differentiates from antibodies addressing this pathway through inhaled delivery directly into the lungs, potentially resulting in convenience, efficacy and safety benefits. Local delivery allows for very low doses, likely also resulting in a significant cost of goods advantage over systemically delivered antibodies. This program currently is in IND-enabling studies and the initiation of a first-in-man clinical trial is anticipated around the middle of 2017. The program is partnered with AstraZeneca, with Pieris retained co-development and co-commercialization options in the USA.